eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2013
vol. 51
 
Share:
Share:
more
 
 
abstract:
Original paper

Etanercept in a therapeutic program for the treatment of rheumatoid arthritis and ankylosing spondylitis – 7 years’ personal experience

Maria Majdan
,
Zofia Kiełbik
,
Renata Seweryn

Reumatologia 2013; 51, 1: 15-19
Online publish date: 2013/03/05
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aim of the study: To investigate the effectiveness and safety of etanercept (ETA) treatment in patients with active rheumatoid arthritis (RA) and ankylosing spondylitis (AS) enrolled in the national therapeutic program.

Material and methods: The study was conducted in 55 adult patients with active RA (DAS28 > 5.8) and 33 adult patients with active AS (BASDAI > 7) who were enrolled in the ETA national therapeutic program as a first (40 RA patients) or second (15 RA patients) line biological therapy. The period of observation of RA patients lasted from 3 months to 9 years, whereas in AS patients it lasted from 1 to 30 months. The safety; rate of long-term remissions and primary or secondary ineffectiveness of ETA treatment were analyzed.

Results: Permanent remission (over 12 months without biological therapy) occurred in a similar percentage of RA patients (5–9%) and AS patients (3–9%). There were 7 non-responders (12.7%) to the initial treatment with ETA in a group of RA patients and 3 (9%) in AS patients (NS). Secondary ineffectiveness of ETA therapy was observed in 19 (34.5%) RA patients and in 2 (6.1%) AS patients. Side effects (infections and allergic skin reactions) were relatively rare, mainly at the beginning of therapy.

Conclusions: We conclude that ETA treatment is a safe and effective form of therapy in patients with active, long-term RA previously treated with various DMARDs, and in patients with active form of AS. Primary ineffectiveness of ETA therapy is relatively rare in RA and AS patients. On the other hand, the secondary ineffectiveness of therapy in RA patients is the reason for its discontinuation in about one-third of patients after ca. 28 months of treatment.
keywords:

etanercept, rheumatoid arthritis, ankylosing spondylitis




Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe